Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Nov 26, 2018 9:00am EST

CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize

Nov 14, 2018 4:03pm EST

CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update

Nov 08, 2018 9:00am EST

CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazine’s Health Care 50

Nov 05, 2018 9:00am EST

CohBar Provides Update on CB4211 Clinical Trial

Oct 31, 2018 9:00am EDT

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018

Sep 25, 2018 9:00am EDT

CohBar Engages LifeSci Advisors as Investor Relations Partner

Aug 14, 2018 4:03pm EDT

CohBar Announces Second Quarter 2018 Financial Results

Aug 02, 2018 1:09pm EDT

CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018

Jul 12, 2018 9:00am EDT

CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH

Jun 27, 2018 4:05pm EDT

CohBar Completes Sale of $20 Million Under Controlled Equity Offering